AGI discontinues lead candidate Rezular for IBS
This article was originally published in Scrip
AGI Therapeutics has discontinued its lead product, Rezular (arverapamil), following its failure to meet the primary endpoint of its Phase III study for diarrhoea-predominant irritable bowel syndrome (IBS-D).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.